Increased Plasma Levels of Free Tissue Factor Pathway Inhibitor in Patients with Graves’ Disease

Eriko Morishita; Takuma Hashimoto; Hidesaku Asakura; Masanori Saito; Masahide Yamazaki; Keiji Aoshima; Tomotaka Yoshida; Hisao Kato; Tamotsu Matsuda

doi:10.1055/s-0037-1615094

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 79(05): 919-923
DOI: 10.1055/s-0037-1615094

Review Article

Schattauer GmbH

Increased Plasma Levels of Free Tissue Factor Pathway Inhibitor in Patients with Graves’ Disease

Authors

Eriko Morishita

¹From the Department of Laboratory Sciences, School of Health Science, Kanazawa University, Kanazawa

²From the Third Department of Internal Medicine, Kanazawa University, Kanazawa
Takuma Hashimoto

³From the Department of Laboratory Medicine, School of Medicine, Kanazawa University, Kanazawa
Hidesaku Asakura

²From the Third Department of Internal Medicine, Kanazawa University, Kanazawa
Masanori Saito

²From the Third Department of Internal Medicine, Kanazawa University, Kanazawa
Masahide Yamazaki

²From the Third Department of Internal Medicine, Kanazawa University, Kanazawa
Keiji Aoshima

²From the Third Department of Internal Medicine, Kanazawa University, Kanazawa
Tomotaka Yoshida

³From the Department of Laboratory Medicine, School of Medicine, Kanazawa University, Kanazawa
Hisao Kato

⁴From the National Cardiovascular Center Research Institute, Osaka, Japan
Tamotsu Matsuda

²From the Third Department of Internal Medicine, Kanazawa University, Kanazawa

Abstract

Summary

Tissue factor pathway inhibitor (TFPI) is present in a free-form and in lipoprotein-associated forms in plasma. In this study, the plasma concentrations of total TFPI (tTFPI) and free-form TFPI (fTFPI) were measured in 25 patients with Graves’ disease and 25 age-matched healthy subjects, and the relationship between thyroid state and plasma TFPI was examined. Plasma concentrations (median) of tTFPI and fTFPI in Graves’ patients who were hyperthyroid were significantly increased compared with Graves’patients who were euthyroid (152 ng/ml versus 124 ng/ml, p <0.01 and 41.3 ng/ml versus 20.2 ng/ml, p <0.0001, respectively), and control subjects (152 ng/ml versus 96 ng/ml, p <0.0001 and 41.3 ng/ml versus 18.7 ng/ml, p <0.0001, respectively). There was no significant difference in plasma fTFPI concentrations between the euthyroid group and the control group. Plasma fTFPI concentrations correlated closely with thyroid hormone (T3) levels in the patients (r = 0.559, p <0.005). Serial measurement of individual patients revealed that plasma concentrations of fTFPI and tTFPI were significantly decreased, reaching normal control values upon attainment of euthyroidism. In conclusion, the close correlation between plasma fTFPI and serum thyroid hormone levels suggests that thyroid hormones might influence the synthesis or metabolism of TFPI on the surface of endothelial cells in patients with Graves’ disease. This is the first report concerning high concentrations of plasma fTFPI in patients with hyperthyroidism.

Full Text

References

References
1 Rogers JS II, Shane SR, Jencks FS. Factor VIII activity and thyroid function. Ann Intern Med 1982; 97: 713-6.
2 Marongiu F, Conti M, Mameli G, Murtas ML, Balzano S, Sorano GG, Mamusa AM, Martino E. Fibrinogen and fibrinotic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest 1988; 11: 723-5.
3 Morikawa YY, Morikawa A, Makino I. Relation of thyroid states and serum thrombomodulin (TM) levels in patients with Graves’ disease: TM, a possible new marker of the peripheral activity of thyroid hormones. J Clin Endocrinol Metab 1993; 76: 609-14.
4 Sandset PM, Abildgaard U. Extrinsic pathway inhibitor: the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-39.
5 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
6 Novotny WF, Palmier M, Wun TC, Broze GJ, Miletich JP. Purification and properties of heparin releasable lipoprotein associated inhibitor. Blood 1991; 78: 394-400.
7 Girard TJ, Broze GJ. Tissue factor pathway inhibitor. Methods in Enzymol. Lorand L, Mann KG. eds. Academic Press; San Diego: 1993. 222, pp 195-209.
8 Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H. An anti tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz (K3) of free form of TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995; 118: 178-82.
9 Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordøy A. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-9.
10 Moor E, Hamsten A, Karpe F, Bävenholm P, Blombäck M, Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 1994; 71: 707-12.
11 Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze Jr GJ. Plasma antigen levels of lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-93.
12 Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibition of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-8.
13 Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Ødegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991; 2: 425-33.
14 Abumiya T, Nakamura S, Takenaka A, Takenaka O, Yoshikuni Y, Miyamoto S, Kimura T, Enjyoji KI, Kato H. Response of plasma tissue factor pathway inihibitor to diet-induced hypercholesterolemia in crab-eating monkeys. Arterioscler Thromb 1994; 14: 483-8.
15 War TA, Warn-Cramer BJ, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: I. Standardization of assay and evaluation of physiological variables. Blood 1989; 74: 201-6.
16 Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hyper-cholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 1991; 11: 138-45.
17 Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada-Shiba M, Koh H, Tsushima M, Yamamoto A, Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia; Relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996; 16: 802-8.
18 Staels B, van Tol A, Chan L, Will H, Verhoeven G, Auwerx J. Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase and low density lipoprotein receptor in rats. Endocrinology 1990; 127: 1144-52.
19 Davidson NO, Carlos RC, Lukaszwicz AM. Apolipoprotein B mRNA editing is modulated by thyroid hormone analogs but not growth hormone administration in the rat. Mol Endcrinol 1990; 4: 779-85.
20 Davidson NO, Powell LM, Wallis SC, Scott J. Thyroid hormone modulates the introduction of a stop codon in rat liver apoprotein B messenger RNA. J Biol Chem 1988; 263: 13482-5.
21 Rogers JS II, Shane SR. Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983; 102: 444-9.